neubas merg ohr pharma began
trade nbse ticker juli
build better mousetrap rna knockdown
initi outperform pt
initi neubas nbse outperform rate
pt believ nbse solv mani technic limit first-
gener antisens oligonucleotid aso allow rapid drug design system
deliveri blood-brain barrier penetr increas cell permeabl abil
access genom loci secondari rna structur highli select therapi
sinc preclin clinic develop aso diseas like hd al
well-establish risks/benefit also well-known believ nbse
abil speed lead molecul huntington diseas myoton
dystrophi preclin drug develop next month
value-cr event investor bullish approach
reason bullish nbse compani patrol platform
allow rapid drug design treat variou medic abnorm system
abil access genom loci secondari rna structur highli
select therapi believ materi advanc first-gen aso
due dilig suggest nbse talent experienc manag
team could well-posit execut compani plan bring
clinic cso dr danith ly expert
develop therapeut potenti peptid nucleic acid pna discov
earli publish extens work hd
act dr robert friedland work includ evalu treatment
strategi neurodegen diseas huntington al among other
also first scientist modul hd phenotyp preclin
mous ceo dietrich stephan industri veteran extens knowledg
precis medicin variou prestigi public founder/co-found
believ profound potenti aso treat diseas current
field first-gen therapi creat hurdl compani like
nbse wherebi technic advantag aso patrol platform
could lead therapi better risk/benefit profil develop divers
diseas like wamd eylea ra humira underscor enthusiasm
main risk thesi manag potenti inabl execut
preclin develop sub-optimal preclin
risk/benefit profil and/or rapid advanc
approach gene editing/ therapi etc see competit section herein
potenti seriou shortcom patrol platform
year price histori nbse
develop next gener gene-
therapi
analyst certif import disclosur see disclosur
initi neubas
outperform rate price target believ nbse
solv mani technic limit first-gener
antisens oligonucletid aso sinc preclin
clinic develop aso variou diseas like hd
al well-establish risks/benefit also well-
known believ nbse abil speed lead molecul
huntington diseas hd myoton
dystrophi preclin drug develop
next month value-cr event investor
bullish approach
nhp data demonstr support efficaci biodistribut
hd
nhp data demonstr support efficaci biodistribut
nhp data ind file phase initiation/enrol track
hd
hd non-human primat nhp data
nhp data
ind file hd
ind file
first patient enrol phase hd first patient enrol
phase
faster expect nhp data/ind filing/phas initi
hd
faster expect nhp data/ind filing/phas initi
nbse manag secur addit non-dilut financ
partnership ngo hd societi america etc
demonstr support efficaci and/or
biodistribut hd
biodistribut
delay nhp data ind file phase initiation/enrol
demonstr support efficaci and/or
price target nbse valu huntington diseas appli multipl high end
rare diseas sale multipl due platform technolog natur nbse peptide-nucl acid antisens oligonucleotid patrol
platform estim world-wide peak sale discount annual assum probabl market
patient/year net price cash/pipelin make valuat use cash incorpor addit financ
support oper
main risk believ stori manag potenti inabl execut preclin develop strategi
risk/benefit profil and/or preclin develop serious hinder progress
clinic rapid advanc type approach gene edit gene therapi etc address high unmet need
hd see competit section seriou shortcom patrol platform order address variou
manufactur risk competit risk strateg risk financ risk liquid small-capit risk
initi coverag neubas nbse
price target market-capit base achiev pt current
believ nbse platform technolog see compani profil
focus approach huntington diseas hd myoton dystrophi lead
signific re-rat compani valuat success bring clinic
candid hd clinic next month
current includ hd valuat assum launch
sale see valuat model assum
penetr hd market across variou geographi world-wide
gain insight preclin develop nbse also expect
clinic candid add program valuat expect
main driver valuat next month clear variou
preclin hurdl give us greater convict nbse platform technolog
drive valuat
believ nbse clear variou preclin hurdl expect consist news
flow public compani provid visibl valuat re-rat
versu variou public compani pursu antisens oligonucleotid aso approach
exhibit exampl antisens out-licens transact
companymarket cap develop initi life late late stagernai mrna etc translat late stagedatecompanydealindicationclin develop licens commercializationsever licens agreementkidney up-front life sciencesdevelop commerci candid neurolog up-front licens agreement candid ga licens agreementhuntington up-front ionislicens agreement candid cardiovascular up-front milestonesnovarti licens agreementspin muscular up-front licens agreementkidney up-front milestonesbay neubas inc
preclin natur nbse current two molecul develop might seem
indic heighten risk profil howev believ year work
founder patrol platform dr danith ly carnegi mellon univers cmu
conduct peptid nucleic acid pna potenti de-risk early-
believ patrol platform meaning improv potenti
pna elucid earli upcom preclin data readout
valid belief earli work dr ly alreadi identifi potenti
differenti approach hd nbse possibl incorpor
nbse focu hd also strength believ compani chief medic offic
dr robert friedland among dr friedland mani accomplish
work modul hd phenotyp preclin mous believ
background hd help nbse speed clinic trial indic
assum make clinic
util dr friedland work nbse alreadi identifi potenti ideal hd
therapi believ could fulfil mani characterist indic
among strength identifi nbse earli potenti hd
system administr penetr deep brain structur
broad tissu uptak system inject
abil access secondari rna structur hd select accord
nbse see abil access secondari structur allow
higher specif mutant allel effect deactiv
disease-rel rna translat damag protein
compani recent award foundat patent enabl patrol-bas
therapi target secondari structur dna rna
foundat patent well
exhibit potenti advantag hd
due dilig suggest nbse talent experienc manag team
potenti solv fairli complex technic challeng limit first-
gener aso inde compani could verg next-gener
approach could open mani diseas modul via patrol platform
exhibit potenti area developmentpatrol platform
main risk believ stori manag potenti inabl execut
preclin develop strategi risk/benefit profil
and/or preclin develop serious hinder progress
clinic rapid advanc type approach gene edit gene
therapi etc address high unmet need hd see competit section
seriou shortcom patrol platform order address
valu huntington diseas appli multipl high
end rare diseas sale multipl due platform technolog natur
nbse peptide-nucl acid antisens oligonucleotid patrol platform estim
world-wide peak sale discount annual assum
probabl market net price cash/pipelin make
valuat use estim cash incorpor addit
financ support oper nbse suffici cash balanc fund oper
believ
believ inflect point nbse valuat proof-of-concept data hd
preclin studi follow ind file
exhibit nbse valuat assumpt
fulli dilut share outstand productww sale yeardiscount ratesal multipleprob marketnpvrisk-adj rate roe nbi index bbg high end rare diseas sale asset pipelin neubas inc
neubas biotechnolog compani focus develop next
gener gene-silenc therapi treat rare genet diseas caus mutant
neubas focus develop antisens oligonucleotid therapi field
neubas pioneer discoveri develop class ribonucl acid
nucleic acid antisens oligonucleotid patrol platform enabl compani
yield effici discoveri drug product candid potenti transform
treatment paradigm peopl affect rare genet diseas initi focu
use patrol platform neubas develop candid
treatment huntington diseas target myoton dystrophi type
repeat expans disord also asset target
secondari rna structur genom dna across varieti rare diseas
decemb neubas in-licens agreement patrol platform
exclusit ip carnegi mellon univers issu cmu common
share cmu hold share juli agreement effect
year ip relat hd
valid possibl extens hatch-waxman term extens
neubas continu build upon strong ip franchis around patrol
found nbse becam list via revers merger ohr
pharmaceut juli compani headquart pittsburgh pa
hold approxim stake nbse
neubas two candid patrol platform preclin develop
huntington diseas
peptid nucleic acid whose size match small-
molecul therapeut enabl broad system distribut
potenti bind mrna hairpin form
repeat underli caus hd whose toxic often show
repeat
avail preclin data abil cross
blood-brain barrier bbb thu lower mutant huntingtin
mhtt protein level system mhtt also
leav wild-typ huntingtin whtt intact
preclin studi conduct expect
result neubas plan file investig
new drug applic ind huntington diseas
believ posit data along phase initi
valid patrol platform becom valuat inflect
point nbse
beyond hd could potenti expand
repeat diseas identif neubas patrol get
valid preclinical/clin data
carri potenti delay and/or halt progress
hd address root caus diseas rather
delay halt progress myoton
dystrophi type address caus rather manag
symptom also patrol-en current preclin
also pna specif bind abnorm
lengthi secondari rna structur form ctg repeat
dmpk gene often interfer normal cell
function note compar hd pathogen
fold repeat keep stack diseas progress
believ patrol work even better longer repeat given
preclin data avail wild type also repeat
current preclin studi nbse plan file ind
drug beyond could potenti
expand cug repeat diseas three identifi
neubas also undisclos asset target indic includ diseas
caus cgn repeat erythermalgia famili parkinson diseas etc besid
total cug expans diseas identifi repeat
expans diseas known neubas patrol platform could
potenti go meanwhil neubas claim short-term execut focu
get hd clinic
exhibit opportun beyond hd
la spada albert paul taylor repeat expans diseas progress puzzl diseas pathogenesi natur review
exhibit clinic molecular characterist inherit neurolog repeat
la spada taylor repeat expans diseas progress puzzl diseas pathogenesi
contain c-termin thioester n-termin cystein increas
bind affin base ligand secondari hairpin rna structur strong
stabl bond also discrimin rcag normal length repeat prove
competit bind assay in-vitro
locat repeatmechan /within genecategori diseasedentatorubral-pallido-seizur choreoathetosi rare mostluysian atrophi drpla ataxia cognit declinepati japanfragil syndrom ofment retard facialhypermethyl ofmost commonment retard autismpromot lofinherit mrfragil tremor ataxiaataxia intent tremor premutationsyndrom fxta parkinsonismcarri onlyfrax mental retardationment retard need x-link mrataxia sensori loss lof phenocopi ofmost commonweak diabet mellitu mitochondri diseaseinherit ataxia inardiomyopathycaucasian ethnicitychorea dystonia cognitiveon mostdeclin psychiatr diseasecommon inheriteddiseas humanshuntington disease-chorea dystonia cognitiverna gof poli aminoa strikinglik gof and/or lof phenocopi hdoculopharyng musculareyelid weak dysphagia modest expansiondystrophi opmd proxim limb weaknesscaus diseasemyoclon epilepsi type myoclonu autosom unverricht-lundborg tonic-clon seizur recess disord gene cstb cerebellar degenerationfinland africamyoton dystrophymuscl weak myotonia musculardiseas mental retardationdystrophymyoton dystrophymuscl weak myotonia strikingtyp muscularproxim limb weak phenotyp includesatrophi sbma lower motor neuron diseaselof androgeninsensitivityspinocerebellar ataxiaataxia dysarthria account ophthalmoplegiaal domin ataxiaspinocerebellar ataxiaataxia slow eye proteintyp motor diseas may resid inoccasion parkinsonismth nucleusspinocerebellar ataxiaataxia dystonia lowermost commontyp neuron diseasedomin ataxiaspinocerebellar ataxiaataxia dysarthria sensorycaus gene encodestyp occasion episodicasubunitof p/q-type ca channelspincerebellar ataxiaataxia dysarthria cone-rodclin distinct astyp retin diseasepati retinaldiseasespinocerebellar ataxiaataxia dysarthria untransl rna /rna gof andmani case oftyp spasticitycod regionpolyglutamin gofreduc penetrancespinocerebellar ataxiaataxia dysarthria seizureshug repeat onlytyp ancestri spinocerebellar ataxiatremor ataxia spastic causal gene encodestyp phosphatasespinocerebellar ataxiaataxia dementia chorea gene tata-bindingtyp dystoniaprotein tbp syndrom non-syndromicment retard alon associ withx-link mental retardationwith seizur withwest partington gene arx dysarthria dystoniasyndromegcgcod regionlik lofcagpromot utr unknowncagcod regionpolyglutamin gofcagcod regionpolyglutamin gofctg cagattctintronrna gof cagcod regionpolyglutamin gofcagcod regionpolyglutamin gofcagcod regionpolyglutamin gofcagcod regionpolyglutamin gofctgintronrna gofcagcod regionpolyglutamin gofpolyglutamin utr codinggcgcod regionpolyalanin goffriedreich ataxia frda gaaintronhuntington diseas hd cagcod regiondiseasemain clinic featurescaus regionpolyglutamin gof neubas inc
exhibit access secondari rna structur hd select
hd patholog site deep brain demonstr deep penetr
brain also organs/tissu system administr anim
model need see anim data hd get color
exhibit brain broad tissu uptak post system inject
target specif secondari structur creat cug repeat
target mutant dmpk allel leav wild type intact exhibit show
in-vitro result competit bind assay perform pictur
left prove probe discrimin expand transcript pathogen length
wild type normal length probe bind occur sequence-specif
manner pictur right show disrupt complex
therefor interven diseas pathway await in-vitro
in-vivo data
aim combin specif antisens oligonucleotid approach deep
intracellular penetration/high cell permeabl get nucleic acid across lipid
bilay broad organ/tissu biodistribut advantag small molecul approach
investor fairli familiar aso approv product spinraza
ioni eteplirsen sarepta antisens oligonucleotid bind particular
region premessag ribonucl acid pre-mrna inhibit translat reduc
product disease-caus protein dna transcrib rna process
call splice occur interven sequenc form mrna remov
exhibit spinraza mechan action aso exampl
howev aso limit instanc even though spinraza consid
one best launch rare diseas drug treat spinal muscular atrophi use
spinraza requir intrathec administr inject spinal canal otherwis
enough amount drug reach nerv cell spinal cord
brain stem control skelet muscl activ huntington diseas site
patholog deep brain locat caudat putamen aso tend
larg cross bbb requir intrathec inject even intracerebr inject
invas also due low uptak tissu aso often need high dosag
show efficaci safeti side aso whose half-liv alter might caus self-
aggreg side effect shown anim model vitro
comparison patrol platform produc shorter version aso solv
hurdl tradit aso approach maintain high specif
achiev broad tissu distribut potenti system administr
note tradit aso alway face tri access secondari
rna structur hairpin loop common element rna secondari
structur contrast neubas pna bind rna secondari even higher
verma ashok recent advanc antisens oligonucleotid therapi genet neuromuscular diseas annal indian academi
smith andersen hovgaard jaroszewski ration select antisens oligonucleotid sequenc eur pharm
gredel ja berger ak walton sp impact target mrna structur sirna silenc effici large-scal studi biotechnol bioeng
behlk chemic modif sirna vivo use oligonucleotid
structur abund cell rna bind form stabl secondari
structur post short probe tight increas
specif mhtt
exhibit advantag patrol tradit aso
peptide-nucl acid invent back artifici synthes
polym similar dna rna creat detach deoxyribos phosphat
backbon dna replac achir polyamid pna
strong bind affin dna rna resist enzym like nucleas
proteas make appeal aso howev pna also
character poor water solubl cell-perm self-aggreg unspecif
bind unfavor featur
mortim kidwel doudna insight rna structur function genome-wid studi gen
thadk shivaji hridya perera dinithi gil roberto mukherje arnab ly hao shape select bifaci recognit
nielsen pe egholm berg rh buchardt decemb sequence-select recognit dna strand displac
neubas pna compos janu base mppna minipeg -- peptid
nucleic-acid backbon capabl bind rcag repeat repeat
sequence-specif select manner via infer bival h-bond
presenc rna target ligand exhibit expect form transient
bival h-bond interact nucleobas rna target next one anoth
result intermolecular base stack step upon cleavag disulfid bond
ligand would undergo template-direct ncl form concaten product bind
rna templat tightli step absenc rna target ligand would self-
deactiv undergo intramolecular ncl reaction form cyclic product step
exhibit bifaci janu base neubas patrol platform
compar previou pna neubas optim novel pna
thadk shivaji et al design bival nucleic acid ligand recognit rna-rep expans associ
make pna higli select bind case h-bond tune
increas select mutant transcript jansu base capabl bind
repeat bival h-bond
individu interact ligand rna weak transient
howev upon instal c-termin thioester n-termin cystin
reduct disulfid bond undergo template-direct nativ
chemic ligat form concaten oligomer product bind tightli
function group like guanidin ad increas solubl decreas
hydrophob
novel pna self-deactiv undergo intramolecular reaction form
cyclic product prevent bind
preclin studi conduct evalu patrol platform technolog
lead program candid area pharmacokinet pharmacodynam
thadk shivaji et al design bival nucleic acid ligand recognit rna-rep expans associ huntington
huntington diseas rare neurodegen disord central nervou system
mark chorea involuntari jerk twitch movement mani
psychiatr disturb get pronounc hd progress
two type hd due differ point time diseas start
peopl hd develop symptom individu adult-
onset form hd live year symptom emerg often
experi troubl walk speak swallow think etc howev less
common form hd known juvenil form case children adolesc
year old hd begin progress quickli adult-
onset set usual live year sign appear juvenil hd
patient experi seizur type patient first experi
worsen function abil suffer cognit psychiatr disord
eventu lose independ die infect pneumonia
complic like unabl swallow
hd autosom domin disord caus inherit defect one singl gene
htt huntingtin gene one copi suffici caus hd htt gene code
product protein call huntingtin whose function well-known
seem play import role nerv cell mutat caus
trinucleotid repeat dna segment made cytosin adenin guanin
appear multipl time row short arm chromosom huntingtin
gene normal peopl segment repeat time howev
segment repeat time hd patient note juvenil hd patient
repeat adult hd patient often repeat even
though except still size segment increas abnorm long
version huntingtin protein produc repeat translat
polyglutamin polyq sequenc n-termin region htt elong
protein cut smaller toxic fragment aggreg togeth deposit
accumul neuron disrupt normal function brain
three lead cytotox mechan hd latter two hypothes
support anim
polyq toxic polyq tend aggreg interact polyq-
contain protein form larg amyloid-lik structur whose unregul
bind sequestr caus problemat cascad molecular cellular
toxic gain rna function upon transcript rgag adopt imperfect
hairpin structur sequest muscleblind-lik protein
altern rna-splic regul protein associ rcag
result complex trap nucleu preclud export
cytoplasm product htt protein
roo raymund huntington diseas clinic review orphanet journal rare diseas volume dec
thadk shivaji et al design bival nucleic acid ligand recognit rna-rep expans associ
protein toxic rcag repeat beyond certain length lead product
toxic polyq polyalanin polya well polyserin poli
exhibit repeat expans mutat hd patient
us nation librari medicin expans compani report
sinc hd inherit diseas alter htt gene also pass one
gener next unfortun repeat increas size higher
repeat number tend associ earlier onset hd side
one gener repeat close hd threshold low children might
high chanc develop hd
huntington diseas diagnosi treatment
huntington diseas straightforward diagnosi patient symptom
normal undergo neurolog test perform rang
neurolog physic function test patient also ask famili
histori hd effect accur test genet test count
repeat hd gene deriv dna taken blood sampl number
repeat support diagnosi hd number rule hd
patient repeat borderlin rang famili member ask
examin genet test famili member result inconclus well
diagnost imag perform comput tomographi ct magnet
reson imag mri scan brain
current avail treatment option hd address symptom rather
caus mani novel therapi develop see competit landscap
section slow stop revers hd tetrabenazin deutetrabenazin
often prescrib treat hd-associ involuntari movement antipsychot drug
risperidon olanzapin etc prescrib chorea citalopram fluoxetin etc
prescrib depress caus hd
current novel treatment develop see target upstream
pathogen principl htt lower howev treatment earlier
small popul trial except roche-ioni compound phase still
box check treatment
accord meta-analysi huntington diseas believ affect peopl per
popul north america estim per
peopl european ancestri hd less common asian countri
averag hd patient juvenil rare form hd one
pringsheim wiltshir day dykeman steev jett incid preval huntington
diseas systemat review metaanalysi disord
quarrel oliv et al preval juvenil huntington diseas review literatur meta-analysi plo current volume
need immedi efficaci treatment number tend conserv
side also studi show hd case juvenil hd
studi suggest higher preval besid one-third hd patient
within earli mid- end stage group base hd progress
mid- end-stag patient tend need foundat therapi
exhibit minimum preval hd global
warbi et al addit refer may view http //www hdinsight org/publ html
sinc hd autosom domin inherit diseas expect peopl get
hd repeat accumul gener gener especi peopl
whose repeat number borderlin expect high singl digit growth
patient number model hd patient-growth percentag tend
underestim hd market size project
disease-modifi therapi symptomat therapi
direct medic cost huntington diseas stage retrospect commerci medicaid claim data analysi journal medic
 huntington diseas hd model usedslow diseas progress normal death occur year upon onsethttp //ghr nlm nih gov/condition/huntington-diseaseu popul bureaeu popul patient progress timepreval north america eu per pringsheim et al us eu less asia baig et al annual hd treatment opportunitiesin hd treatment opportunitiesin stage evenli distribut among patient popul assum mid-lat stage patient get percentag junvenil hd percent hd case juvenil hd patient diseas onset year old die within report project juvenil hd treatment opportun regular hd treatment opporun juvenil hd treatment opportun regular hd treatment opporun growth rate treatment opportun assumptionannu growth rate treatment opportun assumptionannu cost treatment per patient opco assumptionannu cost treatment per patient assum us costpric inflat assumptionpric inflat revenu juvenil hd treatment opportun regular hd treatment opporun juvenil hd treatment opportun regular hd treatment opporun penetr juventi hd penetr regular hd penetr juventi hd penetrationregular hd hd patient treat hd patient treat hd patient treat hd patient treat hd revenu us regular hd revenu us juvenil hd revenu eu regular hd revenu eu total us revenu total eu revenu ww revenu neubas inc
myoton dystrophi inherit autosom domin multisystem disord affect
skelet smooth muscl eye heart endocrin system
common form muscular dystrophi begin adulthood character
exhibit major effect myoton dystrophi type
two type myoton dystrophi type type sign symptom
overlap type milder type muscl weak often affect muscl
lower leg hand neck face type primarili involv neck shoulder
elbow hip caus mutat differ gene dmpk
cnbp categor three
mild character cataract mild myotonia sustain muscl
contract life span normal
classic character muscl weak wast myotonia
cataract often cardiac conduct abnorm adult may becom
physic disabl may shorten life span
congenit character hypotonia sever gener weak
birth often respiratori insuffici earli death intellectu disabl
common
adam mp arding hh pagon ra et al editor seattl wa univers washington seattl
congenit patient mortal rate first month life
surviv chanc contrast classic mild form
averag life span
caus expans ctg trinucleotid repeat non-transl region
dmpk gene make protein call myoton dystrophi protein
kinas play key role cellular commun within heart brain muscl
cell mutat dmpk gene produc expand version dmpk mrna
turn form clump insid cell due abnorm length protein function
also suffer loss etiolog dm attribut rna
upon transcript expand rcug repeat rcug adopt imperfect hairpin
structur sequest muscleblind-lik protein key rna splice regul
associ result complex trap nucleu
preclud export cytoplasm product dmpk protein well
prevent perform normal physiolog function
repeat length goe higher occur normal rang
lifetim sinc expand repeat tract stabl repeat even go
thousand also import therapi access secondari structur
creat cug repeat specif target mutant allel
exhibit rna silenc
reardon et al natur histori congenit myoton dystrophi mortal long term clinic aspect archiv diseas
hsieh wei-ch et al design nucleic acid probe cooper bind rna-rep transcript associ
harper shaw housman molecular basi myoton dystrophi expans trinucleotid ctg repeat
end transcript encod protein kinas famili member cell
affect approxim everi peopl around
common type like hd pass one gener next diseas
gener begin earlier life even sever symptom
peopl muscl weak undergo molecular genet test dmpk repeat
length abnorm robust treatment avail
specif howev kind option manag symptom
symptom cataract heart problem myotonia
includ model yet includ updat becom
avail nbse
theadom rodrigu roxburgh balalla higgin bhattacharje jone krishnamurthi feigin preval muscular
activ laquinimod daili oral immunomodulatori small molecul drug
activ select aryl hydrocarbon receptor ahr target neurodegener
inflamm laquinimod downregul inflammatori monocyt microgli
astrocyt activ suppress nf-b activ upregul bdnf brain-deriv
neurotroph factor one mice model show increas bdnf striatum
laquinimod anoth mice model show increas bdnf motor
cortex laquinimod note area brain affect hd set
addit believ inflamm kill nerv cell hd
juli announc phase legato-hd trial hd fail
meet primari endpoint chang baselin uhdrs-tm unifi
huntington diseas rate scaletot motor score month treatment
poster ehdn howev studi meet secondari endpoint
percent reduct caudat volum loss name brain atrophi also laquinimod
demonstr good safeti profil studi well previou clinic studi
ms exploratori endpoint treatment effect mri brain volum q-motor
measur suggest effect laquinimod
insight mechan laquinimod action brck et al journal neurolog scienc volum issu
ellrichmann gisa et al laquinimod treatment mous model scientif report volume jul
companyproductdevelop stageindicationnoteact biotechlaquinimodphas completedhuntington diseasea small molecul activ select aryl hydrocarbon receptor meet primari endpoint slow diseas develop secondari endpoint reduct brain atrophi met develop discontinu develop planaop orphan privat slisistat completedhuntington diseasean oral activ select inhibitor safe toler phase phase studi efficaci result report develop planazevan ongoinghuntington diseasea vasopressin receptor antagonist cross blood-brain barrier follow oral administr result pendingioni rocheionis-httrx ongoinghuntington diseasean antisens drug reduc product form huntingtin htt protein irrespect individu htt mutat nuredi privat undisclosedpreclinicalhuntington huntington diseasean antisens oligonucleotide-bas therapeut approach activ altern htt splice-isoform htt disrupt critic cleavag site thu prevent format toxic n-termin fragment mutant huntingtin mhtt toxicitysag ongoinghuntington diseasean oxysterol-bas posit alloster modul pam n-methyl-d-aspart nmda receptor endogen modul nmda receptor functionsangamo takedaundisclosedpreclinicalhuntington diseasea zfp-tf gene therapi diseasean vector carri artifici micro-rna specif inhibit product mutant protein ongoinghuntington diseasea monoclon antibodi monthli iv protein semaphorin block activ prevent activ microglia astrocyt main inflammatori cell brainvoyag sanofi huntington diseasecompos adeno-associ viru capsid transgen har rna interfer pathway select knock reduc level htt mrnawav life scienc ongoinghuntington diseasestereopur antisens oligonucleotid intrathec administr select target mutant huntingtin htt mrna transcript snp snp respect neubas inc
activ biotech develop plan laquinimod activ biotech
out-licens regain licens
multipl failur hd multipl sclerosi clinic studi activ biotech current
seek partnership commerci develop laquinimod hd
aop orphan selisistat oral small molecul select inhibitor inhibit
recombin human silent inform regul member
sirtuin deacetylas famili remov acetyl group lysin residu histon
protein includ mutant htt mice shown inhibit
result select decreas mutant htt protein level without affect level
normal protein
previou phase studi patient earli stage hd
random receiv high/low dose selisistat placebo day
exploratori studi pd biomark circul solubl huntingtin innat immun
marker studi result publish selisistat found
safe well-toler dose studi howev statist
signific treatment effect base immun marker solubl htt
conclud efficaci studi need selisistat
develop plan announc aop orphan selisistat
azevan pharma oral small molecul antagonist block vasopressin
receptor cross blood-brain barrier studi
vasopressin small molecul mani speci includ human normal produc
believ involv social emot behavior hd patient
much vasopressin made sinc receptor main receptor vasopressin
block receptor might viabl moa neuropsychiatr symptom hd
one preclin show strong abil cross bbb
current studi phase studi evalu
toler safeti effect treatment irrit mood peopl
hd toler safeti primari secondari endpoint sever
measur behavior symptom
although clinicaltri gov shown recruit complet octob
studi compani given updat data/develop
plan believ efficaci studi follow
roch partner intrathecal-administ
second-gener antisens oligonucleotid design bind
faulti htt mrna reduc product toxic mhtt protein mechan
call pre-mrna degrad rather target symptom hd
target caus base anim reduct htt mrna lead lower
pallo judit et al inhibit specif hdac sirtuin suppress pathogenesi drosophila model huntington diseas
sssmuth sigurd et al exploratori double-blind random clinic trial selisistat inhibitor patient
huntington diseas british journal clinic pharmacolog volume
guillon christoph et al azetidinon vasopressin antagonist bioorgan medicin chemistri volume
guillon christoph et al azetidinon vasopressin antagonist bioorgan medicin chemistri volume
kordasiewicz holli et al sustain therapeut revers huntington diseas transient repress huntingtin synthesi neuron
htt concentr amelior hd phenotyp ioni state base
rodent non-human primat studi mhtt reduct
cerebrospin fluid csf predict result reduct cortex
brain mhtt highli express note lower mutant htt
wild type htt might concern normal huntingtin protein play import role
death mice shown one huntingtin absent
ionis-httrx previous complet phase studi
primari endpoint safeti secondari httrx pk csf accord studi
result publish ionis-httrx well toler signific
advers event sae report signific dose-depend reduct mhtt
observ csf mhtt reduct mean mg
arm chang baselin csf neurofila light chain nlp concentr one
exploratori outcom elev nlp concentr csf occur
patient cohort day day although never explain
nlp concentr csf gener return baselin start extens
studi start month final dose phase trial
particip trial offer enrol open-label extens studi
evalu effect intrathec administr mg dose either
month everi month
exhibit concentr mhtt csf phase studi
current phase studi recruit patient
three group dose everi week everi week placebo everi
week month primari endpoint chang composit unifi
 nasir et al target disrupt huntington diseas gene result embryon lethal behavior morpholog
chang heterozygot cell pp
huntington diseas rate scale cuhdr total function capac score
week meanwhil open-label extens also initi
roch licens ionis-httrx ioni decemb roch respons
develop cost ioni gener up-front mileston payment well
royalti commerci januari announc first patient
enrol pivot studi hd patient
proqr antisens oligonucleotide-bas therapeut approach
mitig mhtt toxic maintain physiolog htt function activ
altern exon splice isoform htt remov cleavag site
hypothes main contributor hd toxic n-termin fragment
form cascad proteolyt cleavag initi cleavag
current still discoveri avail data poster demonstr
abil activ htt maintain wild type htt mice
small molecul oxysterol-bas posit alloster
modul pam n-methyl-d-aspart nmda receptor nmsd receptor
ionotrop glutam receptor play key role host cognit behavior
current open-label phase studi hd patient
follow healthy-volunt studi pk safeti
pk profil support once-daili dose effect
electrophysiolog function imag cognit endpoint attenu effect
ketamin brain circuit also healthi volunt dose exhibit
superior perform test work memori complex problem solv pk data
support once-daili dose await develop plan hd indic
specif
exhibit attenu effect ketamin brain circuit
klein karneva toonen et al novel antisens oligonucleotid therapi design prevent hd patholog
maintain htt function journal neurolog neurosurgeri psychiatri
sangamo takeda preclin asset
undisclos howev like could zfp-tf gene therapi juli
sangamo announc activ diseas allele-select zinc finger protein
preclin model hd publish journal natur medicin
demonstr zfp-tf select repress hd-caus allel
differ dose preserv normal allel patient-deriv
fibroblast neuron
uniqur consist adeno-associ viral vector serotyp
mihtt carri artifici micro-rna specif inhibit product
mutant protein mhtt present preclin data transgen hd tghd minipig
sustain month mhtt protein lower sever brain region
one-tim intrastriat administr target accumul
htt fragment toxic sourc abnorm protein aggreg
exhibit moa
current phase studi adult earli manifest
hd also first clinical-stag gene therapi program patient
zeitler bryan et al allele-select transcript repress mutant htt treatment huntington diseas natur news
neueder andrea et al pathogen exon htt protein produc incomplet splice huntington diseas patient scientif
receiv rest placebo month although goal
last efficaci life-long mhtt reduct risk also trivial amt-
seem way switch treatment avoid safeti issu might
also life-long
vaccinex pepinemab monoclon antibodi monthli iv
protein semaphorin block activ
prevent activ microglia astrocyt main inflammatori cell
brain earli preclin data show treatment inhibit cortic
corpu callosum degener mice brain
current phase studi patient earli manifest
huntington diseas cohort patient finish provid
data determin requir sampl size treatment durat cohort
cohort safeti signal observ reduc atrophi improv
multipl motor cognit assess also seen cohort
last patient visit cohort expect juli accord vaccinex
voyag sanofi genzym compos adeno-associ viru
capsid transgen har rna interfer pathway select
knock reduc level htt mrna accord preclin studi mice
result aav vector reach cell mous brain
mirna transgen success reduc level htt mice anoth also
support find
takeda stereopur
antisens oligonucleotid intrathec administr select target mutant
huntingtin htt mrna transcript snp snp
snp shown select mhtt wthtt wild type select
achiev target frequent associ mutant htt
expans htt gene frequent allel link three differ
collect thought present least gene expans carrier
stanek lisa et al silenc mutant huntingtin adeno-associ virus-medi rna interfer amelior diseas
manifest mous model huntington diseas gene therapi volume
hadaczek piotr et al widespread transgen express nonhuman primat brain implic
kay chri et al huntingtin haplotyp provid priorit target panel allele-specif silenc huntington diseas patient
european ancestri molecular therapi journal american societi gene therapi volume
rodrigu filip edward wild huntington diseas clinic trial corner februari journal huntington diseas volume
exhibit preclin data mhtt wthtt reduct
asset current phase studi
respect patient receiv differ dose
level placebo directli inject spinal canal
primari object two trial assess safeti toler
intrathec dose respect earli manifest hd
patient day addit object includ measur total htt protein
mutant htt protein exploratori pk/pd clinic mri endpoint fda
instruct conduct preclin studi order clear mad
multiple-ascend dose studi guid top-line readout earli
respect studi
amo pharma small molecul inhibitor glycogen synthas kinas
inhibit shown correct activ regulatori protein
muscl cell deficit anim model
complet phase studi previous current
plan pivot phase studi look pivot trial
start recruit yet podium present confer
neurolog neuromuscular diseas result phase studi suggest
dose mg novel oral glycogen synthas kinas enzym
inhibitor render clinic benefit major patient treatment
period four efficaci variabl assess includ grip strength clinician visual
analogu scale rate caregiv top concern rate scale ohio state univers
clinic global impress improv rate scale differ favor
dose dose worsen remain variabl
audent therapeut seem combin vector rna knockdown
vector exon skip name use aav deliveri rna knockdown exon
skip goal prevent accumul toxic dmpk rna ctg repeat
restor muscl cell function
current preclin studi audent guid file ind
jone karli et al mediat muscl patholog myoton dystrophi journal clinic investig volume
companyproductdevelop stageindicationnoteamo pharma tideglusib phase ongoingmyoton dystrophi type small molecul inhibitor glycogen synthas kinas whose inhibit could revers cognit behavior deficit symptom hdaudent ind guid file dystrophi type aav-antisens gene therapi programavid bioscienc privat undisclosedpreclinicalmyoton dystrophi type antibody-oligonucleotid conjug carri dmpk sirna reduc express toxic dmpk mrna contain cug repeat expansionsdyn privat undisclosedpreclinicalmyoton dystrophi type antibody-oligonucleotid conjugatevertex pharmaceut crispr undisclosedpreclinicalmyoton dystrophi type gene edit programlocana privat undisclosedpreclinicalmyoton dystrophi undisclosedfulcrum discoverypreclinicalmyoton dystrophyundisclosedexpans ongoingmyoton dystrophin type small molecul rna inhibitor bind cug specif free muscleblind-lik famili rna bind protein regul pre-messag rna splicingnexien file soonmyoton dystrophincannabinoid formul neubas inc
expans therapeut small molecul rna inhibitor bind cug
specif free muscleblind-lik famili rna bind protein mb regul
pre-messag rna splice encod protein skelet muscl cardiac nerv
patient abnorm structur form contain long cug repeat
bind sequest member mb mous model shown
restor mb function revers muscl
current double-blind placebo-control phase studi
patient primari endpoint safeti toler
secondari endpoint assess effect stanford
sleepi scale score psychomotor vigil task one-back task compar
holt ian et al muscleblind-lik protein similar differ normal myoton dystrophi muscl american journal
kanadia rahul et al revers rna missplic myotonia muscleblind overexpress mous poli cug model
myoton dystrophi proceed nation academi scienc unit state america volume
dr industri veteran consid one father field
precis medicin train leadership human genom project
nih go lead discoveri research translat genom
research institut serv professor chairman depart human
genet univers pittsburgh identifi molecular basi
dozen genet diseas publish extens journal scienc
new england journal medicin natur genet pna cell parallel dr
found co-found biotechnolog compani advis
addit compani compani back top-tier investor
sequoia capit kpcb thiel capit khosla ventur well corpor partner
mayo clinic dr receiv ph
univers pittsburgh bs carnegi mellon univers
dr ly primari inventor neubas patrol platform year
research develop experi nucleic acid chemistri function genom
extens public report work appear numer high-profil
proceed nation academi scienc journal american
chemic societi current professor chemistri found director
biomolecular design discoveri institut bdi carnegi mellon univers dr ly
hold ph organ chemistri georgia institut technolog
complet postdoctor fellowship univers california berkeley
scripp research institut genom age-rel genet diseas respect
dr friedland renown neurologist prior neubas becam fourth
chairman depart neurolog surgeon univers pittsburgh
school medicin univers pittsburgh medic center prior join
depart dr friedland professor neurosurgeri harvard medic school
vice-chairman neurosurgeri associ director cerebrovascular surgeri
brigham women hospit boston present walter dandi professor
neurosurgeri neurolog neurobiolog co-director upmc neurolog
institut work publish mani top tier journal includ natur scienc
natur medicin natur neurosci pna recogn
mani academ award elect member prestigi american
societi clinic investig dr friedland one three neurosurgeon
elect member american associ physician
elect nation academi medicin
backenroth chief offic svp busi develop
mr backenroth extens execut experi financ build
biotechnolog compani recent come ohr pharmaceut
ohr instrument compani growth start-up market capit
sever hundr million move product preclin late stage clinic
develop previous work invest banker benchmark
compani llc invest bank firm special micro-cap biotechnolog
transact benchmark help numer small biotechnolog compani
rais equiti growth capit varieti structur mr backenroth also act
advisor multipl public privat biotechnolog pharmaceut compani
assist busi develop activ joint ventur licens strateg
partnership merger acquisit graduat honor touro colleg
bs financ
robert zamboni ph chief preclin develop
dr zamboni year experi pharmaceut biotechnolog
industri career devot chemistri drug discoveri result
mani compound clinic develop public patent
previous serv vice presid research senior research chemist
merck co inc adjunct professor chemistri mcgill univers dr
zamboni member american chemic societi recipi numer
prestigi award includ prix galien prix lionel-boulet hero
chemistri award american chemistri societi recognit work
discov develop singulair treatment asthma dr zamboni receiv
bsc honor chemistri phd organ synthesi mcgill univers
complet postdoctor fellowship univers pittsburgh yale univers
stock price compani mention report
fulli dilut share outstand productww sale yeardiscount ratesal multipleprob marketnpvrisk-adj rate roe nbi index bbg high end rare diseas sale asset pipelinetot nbse outperform
neubas statement thousand except per share sales- collabor revenue- licens revenue- total revenues- gener research depreci loss impair goodwill- settlement liabilities- total oper oper income- interest total incom loss provis benefit incom tax net incom dilut share outstand neubas inc
neubas balanc cash prepaid expens current total current equip intang asset total account payabl accru expens note payable- total current non-curr liabilities- total prefer stock seri share author par valu share issu outstand respectively- common stock share author par valu share issu outstand cmmon stock rais rounds- addit paid-in accumul deficit total sharehold total liabil sharehold balanc check- nbse outperform
neubas flow incom common stock issu services- stock option warrant amort intang asset prepaid expens current settlement liabilities- loss sale properti equipment- loss impair goodwil account receiv account payabl accru net cash use oper purchas properti equipment- net cash use invest activities- proce warrant exercis cash- proce sale common stocks- repay short-term note net cash use financ decreas cash cash cash equivalentsbegin cash equivalentsend interest paid incom taxes- financ insur premium issuanc short term notes- neubas inc
